Preparing anti-SARS-CoV-2 agent EIDD-2801 by a practical and scalable approach, and quick evaluation via machine learning [PDF]
Acta Pharmaceutica Sinica B, 2021 EIDD-2801 is an orally bioavailable prodrug, which will be applied for emergency use authorization from the U.S. Food and Drug Administration for the treatment of COVID-19.
Zhiyu Li, Xi Feng, Jinlei Bian
exaly +4 more sources
EIDD-2801 resists to infection and co-infection of SARS-CoV-2 and influenza virus [PDF]
Virology JournalBackground The coronavirus disease 2019 (COVID-19) pandemic has exerted a catastrophic impact on public health. Meanwhile, the seasonal influenza outbreak overlaps with the current pandemic wave.
Gao Yuwei
exaly +3 more sources
Molnupiravir and Its Active Form, EIDD-1931, Show Potent Antiviral Activity against Enterovirus Infections In Vitro and In Vivo [PDF]
Viruses, 2022 Enterovirus infections can cause hand, foot, and mouth disease (HFDM), aseptic meningitis, encephalitis, myocarditis, and acute flaccid myelitis, leading to death of infants and young children.
Wu Zhong, Ruiyuan Cao, Yunzheng Yan
exaly +4 more sources
Short Synthesis of Molnupiravir (EIDD-2801) via a Thionated Uridine Intermediate [PDF]
ACS Omega, 2021 Somnath Yadav, Parthasarathi Das
exaly +3 more sources
Open label clinical trial of orally administered molnupiravir as a first‐line treatment for naturally occurring effusive feline infectious peritonitis [PDF]
Journal of Veterinary Internal MedicineBackground Before the discovery of effective antiviral drugs, feline infectious peritonitis (FIP) was a uniformly fatal disease of cats. Multiple antiviral treatments have been recognized, but optimization of treatment protocols is needed.
Krystle L. Reagan +5 more
doaj +3 more sources
Progress Toward a Large-Scale Synthesis of Molnupiravir (MK-4482, EIDD-2801) from Cytidine [PDF]
ACS Omega, 2021 Grace Ahlqvist +2 more
exaly +3 more sources
Accelerated first-in-human clinical trial of EIDD-2801/MK-4482 (molnupiravir), a ribonucleoside analog with potent antiviral activity against SARS-CoV-2 [PDF]
Trials, 2021 A recently published article described the safety, tolerability, and pharmacokinetic profile of molnupiravir (Painter et al. 2021), a novel antiviral agent with potent activity against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the ...
Wendy Holman +6 more
doaj +2 more sources
CPT: Pharmacometrics & Systems Pharmacology, 2023 Effective antiviral treatments for coronavirus disease 2019 (COVID‐19) are needed to reduce the morbidity and mortality associated with severe acute respiratory syndrome‐coronavirus 2 (SARS‐CoV‐2) infection, particularly in patients with risk factors for
Sébastien Bihorel +20 more
doaj +2 more sources
Antiviral activity of molnupiravir against COVID-19: a schematic review of evidences [PDF]
Bulletin of the National Research Centre, 2022 Background The study was aimed at encapsulating the evidence of in vitro and in vivo antiviral activities of molnupiravir and its active form against highly pathogenic SARS-CoV-2, the pathogen responsible for COVID-19, and finding out the efficacy and ...
Shivali Singla, Sachin Goyal
doaj +2 more sources
Update on Treatment of Feline Infectious Peritonitis: European Advisory Board on Cat Diseases (ABCD) Guidelines [PDF]
VirusesFeline infectious peritonitis (FIP) is a disease arising as a result of feline coronavirus infection. It used to be regarded a fatal disease, with euthanasia commonly recommended following diagnosis due to its very poor prognosis.
Séverine Tasker +15 more
doaj +2 more sources